Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients

Tomas Uher, Kelly Fellows, Dana Horakova, Robert Zivadinov, Manuela Vaneckova, Lukas Sobisek, Michaela Tyblova, Zdenek Seidl, Jan Krasensky, Niels Bergsland, Bianca Weinstock-Guttman, Eva Havrdova, Murali Ramanathan

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The purpose of this work was to determine whether changes in cholesterol profiles after interferon-β (IFN-β) 1a treatment initiation following the first demyelinating event suggestive of multiple sclerosis are associated with clinical and MRI outcomes over 4 years. A group of 131 patients (age: 27.9 ± 7.8 years, 63% female) with serial 3-monthly clinical and 12-monthly MRI follow-ups over 4 years were investigated. Serum cholesterol profiles, including total cholesterol (TC), HDL cholesterol (HDL-C), and LDL cholesterol (LDL-C) were obtained at baseline, 1 month, 3 months, and every 6 months thereafter. IFN-β1a initiation caused rapid decreases in serum HDL-C, LDL-C, and TC within 1 month of IFN-β1a initiation (all P < 0.001) that returned slowly toward baseline. In predictive mixed model analyses, greater percent decreases in HDL-C after 3 months of IFN-β1a treatment initiation were associated with less brain atrophy over the 4 year time course, as assessed by percent brain volume change (P < 0.001), percent gray matter volume change (P < 0.001), and percent lateral ventricle volume change (P = 0.005). Decreases in cholesterol biomarkers following IFN-β1a treatment are associated with brain atrophy outcomes over 4 years. Pharmacological interventions targeting lipid homeostasis may be clinically beneficial for disrupting neurodegenerative processes.

Original languageEnglish
Pages (from-to)403-411
Number of pages9
JournalJournal of Lipid Research
Volume58
Issue number2
DOIs
Publication statusPublished - 2017

Fingerprint

Interferons
Multiple Sclerosis
Cholesterol
Lipids
HDL Cholesterol
Brain
Serum
Magnetic resonance imaging
LDL Cholesterol
Atrophy
Lateral Ventricles
Biomarkers
Homeostasis
Therapeutics
Pharmacology

Keywords

  • Brain atrophy
  • Cholesterol
  • Magnetic resonance imaging

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Cell Biology

Cite this

Uher, T., Fellows, K., Horakova, D., Zivadinov, R., Vaneckova, M., Sobisek, L., ... Ramanathan, M. (2017). Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients. Journal of Lipid Research, 58(2), 403-411. https://doi.org/10.1194/jlr.M072751

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients. / Uher, Tomas; Fellows, Kelly; Horakova, Dana; Zivadinov, Robert; Vaneckova, Manuela; Sobisek, Lukas; Tyblova, Michaela; Seidl, Zdenek; Krasensky, Jan; Bergsland, Niels; Weinstock-Guttman, Bianca; Havrdova, Eva; Ramanathan, Murali.

In: Journal of Lipid Research, Vol. 58, No. 2, 2017, p. 403-411.

Research output: Contribution to journalArticle

Uher, T, Fellows, K, Horakova, D, Zivadinov, R, Vaneckova, M, Sobisek, L, Tyblova, M, Seidl, Z, Krasensky, J, Bergsland, N, Weinstock-Guttman, B, Havrdova, E & Ramanathan, M 2017, 'Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients', Journal of Lipid Research, vol. 58, no. 2, pp. 403-411. https://doi.org/10.1194/jlr.M072751
Uher, Tomas ; Fellows, Kelly ; Horakova, Dana ; Zivadinov, Robert ; Vaneckova, Manuela ; Sobisek, Lukas ; Tyblova, Michaela ; Seidl, Zdenek ; Krasensky, Jan ; Bergsland, Niels ; Weinstock-Guttman, Bianca ; Havrdova, Eva ; Ramanathan, Murali. / Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients. In: Journal of Lipid Research. 2017 ; Vol. 58, No. 2. pp. 403-411.
@article{0578747dd6aa4bb387432cc687c7cab9,
title = "Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients",
abstract = "The purpose of this work was to determine whether changes in cholesterol profiles after interferon-β (IFN-β) 1a treatment initiation following the first demyelinating event suggestive of multiple sclerosis are associated with clinical and MRI outcomes over 4 years. A group of 131 patients (age: 27.9 ± 7.8 years, 63{\%} female) with serial 3-monthly clinical and 12-monthly MRI follow-ups over 4 years were investigated. Serum cholesterol profiles, including total cholesterol (TC), HDL cholesterol (HDL-C), and LDL cholesterol (LDL-C) were obtained at baseline, 1 month, 3 months, and every 6 months thereafter. IFN-β1a initiation caused rapid decreases in serum HDL-C, LDL-C, and TC within 1 month of IFN-β1a initiation (all P < 0.001) that returned slowly toward baseline. In predictive mixed model analyses, greater percent decreases in HDL-C after 3 months of IFN-β1a treatment initiation were associated with less brain atrophy over the 4 year time course, as assessed by percent brain volume change (P < 0.001), percent gray matter volume change (P < 0.001), and percent lateral ventricle volume change (P = 0.005). Decreases in cholesterol biomarkers following IFN-β1a treatment are associated with brain atrophy outcomes over 4 years. Pharmacological interventions targeting lipid homeostasis may be clinically beneficial for disrupting neurodegenerative processes.",
keywords = "Brain atrophy, Cholesterol, Magnetic resonance imaging",
author = "Tomas Uher and Kelly Fellows and Dana Horakova and Robert Zivadinov and Manuela Vaneckova and Lukas Sobisek and Michaela Tyblova and Zdenek Seidl and Jan Krasensky and Niels Bergsland and Bianca Weinstock-Guttman and Eva Havrdova and Murali Ramanathan",
year = "2017",
doi = "10.1194/jlr.M072751",
language = "English",
volume = "58",
pages = "403--411",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "2",

}

TY - JOUR

T1 - Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients

AU - Uher, Tomas

AU - Fellows, Kelly

AU - Horakova, Dana

AU - Zivadinov, Robert

AU - Vaneckova, Manuela

AU - Sobisek, Lukas

AU - Tyblova, Michaela

AU - Seidl, Zdenek

AU - Krasensky, Jan

AU - Bergsland, Niels

AU - Weinstock-Guttman, Bianca

AU - Havrdova, Eva

AU - Ramanathan, Murali

PY - 2017

Y1 - 2017

N2 - The purpose of this work was to determine whether changes in cholesterol profiles after interferon-β (IFN-β) 1a treatment initiation following the first demyelinating event suggestive of multiple sclerosis are associated with clinical and MRI outcomes over 4 years. A group of 131 patients (age: 27.9 ± 7.8 years, 63% female) with serial 3-monthly clinical and 12-monthly MRI follow-ups over 4 years were investigated. Serum cholesterol profiles, including total cholesterol (TC), HDL cholesterol (HDL-C), and LDL cholesterol (LDL-C) were obtained at baseline, 1 month, 3 months, and every 6 months thereafter. IFN-β1a initiation caused rapid decreases in serum HDL-C, LDL-C, and TC within 1 month of IFN-β1a initiation (all P < 0.001) that returned slowly toward baseline. In predictive mixed model analyses, greater percent decreases in HDL-C after 3 months of IFN-β1a treatment initiation were associated with less brain atrophy over the 4 year time course, as assessed by percent brain volume change (P < 0.001), percent gray matter volume change (P < 0.001), and percent lateral ventricle volume change (P = 0.005). Decreases in cholesterol biomarkers following IFN-β1a treatment are associated with brain atrophy outcomes over 4 years. Pharmacological interventions targeting lipid homeostasis may be clinically beneficial for disrupting neurodegenerative processes.

AB - The purpose of this work was to determine whether changes in cholesterol profiles after interferon-β (IFN-β) 1a treatment initiation following the first demyelinating event suggestive of multiple sclerosis are associated with clinical and MRI outcomes over 4 years. A group of 131 patients (age: 27.9 ± 7.8 years, 63% female) with serial 3-monthly clinical and 12-monthly MRI follow-ups over 4 years were investigated. Serum cholesterol profiles, including total cholesterol (TC), HDL cholesterol (HDL-C), and LDL cholesterol (LDL-C) were obtained at baseline, 1 month, 3 months, and every 6 months thereafter. IFN-β1a initiation caused rapid decreases in serum HDL-C, LDL-C, and TC within 1 month of IFN-β1a initiation (all P < 0.001) that returned slowly toward baseline. In predictive mixed model analyses, greater percent decreases in HDL-C after 3 months of IFN-β1a treatment initiation were associated with less brain atrophy over the 4 year time course, as assessed by percent brain volume change (P < 0.001), percent gray matter volume change (P < 0.001), and percent lateral ventricle volume change (P = 0.005). Decreases in cholesterol biomarkers following IFN-β1a treatment are associated with brain atrophy outcomes over 4 years. Pharmacological interventions targeting lipid homeostasis may be clinically beneficial for disrupting neurodegenerative processes.

KW - Brain atrophy

KW - Cholesterol

KW - Magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=85011284377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011284377&partnerID=8YFLogxK

U2 - 10.1194/jlr.M072751

DO - 10.1194/jlr.M072751

M3 - Article

AN - SCOPUS:85011284377

VL - 58

SP - 403

EP - 411

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 2

ER -